Clinical study of tirofiban in treatment of high-risk non-ST elevation acute coronary syndrome around perioperative period intervention
- VernacularTitle:替罗非班治疗围介入术期高危非ST段抬高型急性冠脉综合征的效果研究
- Author:
Su ZHANG
;
Bin YAO
- Publication Type:Journal Article
- Keywords:
acute coronary syndrome;
circumference of interventional procedures;
tirofiban;
clinical effects
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(3):105-107
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of tirofiban in treatment of patients with high-risk non-ST-segment elevation of acute coronary syndrome (NSTE ACS),in order to improve the level of treatment effect. Methods 90 cases with high-risk NSTE ACS from January 2011 to April 2013 were randomly divided into control group and observation group. The control group were received treatments of conventional aspirin,clopidogrel, anticoagulation,coronary angiography (CAG)and percutaneous coronary intervention (PCI),while the observation group were added tirofiban therapy an the basis of control group. After the treatment,the differences of cardiovascular adverse events,thrombolysis in myocardial infarction (TIMI)flow grade and complications in both two group were observed and compared. Results There were significant differences in major adverse cardiovascular events in the distal vascular blockage,surgery without reflux,recurrent angina and myocardial infarction and post-PCI TIMI flow grade 2 and 3 (P<0.05),but not in bleeding complications,TIMI flow grade 0 and 1 before and after PCI treatment. Conclusion Tirofiban is safe and effective in treatment of high-risk NSTE ACS in interventional procedures. It can improve TIMI flow, increase tissue perfusion and reduce postoperative complications.
